A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

Item

http://www.wikidata.org/entity/Q35848351

Q35848351

about

Update on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphoma 90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityr Hematopoietic cell transplantation for B-cell lymphoma: an update Radioimmunotherapy of human tumours Ibritumomab tiuxetan for non-Hodgkin's lymphoma.Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma.Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphoma.Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas.Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab.Outcomes after (90) Yttrium-ibritumomab tiuxetan-BEAM in diffuse large B-cell lymphoma: a meta-analysis.Dosimetric considerations in radioimmunotherapy and systemic radionuclide therapies: a review.A phase I study of a combination of yttrium-90-labeled anti-carcinoembryonic antigen (CEA) antibody and gemcitabine in patients with CEA-producing advanced malignancies Radiation Dosimetry Study of [(89)Zr]rituximab Tracer for Clinical Translation of B cell NHL Imaging using Positron Emission Tomography.Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET.Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray".Review of clinical radioimmunotherapy.Advances in the treatment for haematological malignancies.High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma.Current management of follicular lymphomas.Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma.Lymphoid reconstruction and vaccines.Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the Incidence, risk factors, and pathogenesis of second malignancies in patients with non-Hodgkin lymphoma.Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive B-cell lymphoma.Current status and future perspectives for yttrium-90 ((90)Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma.Radioimmunotherapy-based conditioning regimens for stem cell transplantation Front-line therapy for nonlocalized diffuse large B-cell lymphoma: what has been demonstrated and what is yet to be established.High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience.Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates.Autologous stem cell transplantation using a modified TAM conditioning regimen for clinically aggressive non-Hodgkin's lymphoma.Role of hematopoietic stem cell transplant in the management of follicular lymphoma.Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma: current status and future prospects.Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial.A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies.Advances in the treatment of hematologic malignancies using immunoconjugates Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications.Diversity in antibody-based approaches to non-Hodgkin lymphoma.Transplantation for non-Hodgkin lymphoma.Hematopoietic cell transplantation for lymphomas.Recent progress: hematopoietic cell transplant for diffuse large B-cell lymphoma.

P2860

Q24633710-4CEFF767-FECF-4633-864F-42D0DE46E2E7 Q26776480-5DE70CD8-72A2-4FA1-8F94-ACB93AEBE0CA Q27026617-574ACD1A-8168-43A1-83CC-499138B71348 Q28088825-2A50BD75-A690-428B-AED4-2A91F3B4DFFA Q33371489-9555665F-527A-4317-B97C-54F8DD6A4800 Q33405631-1BCBCE3E-5A6C-403B-AEAA-F9079A7A1286 Q33605275-B658E620-B676-4A7F-B119-56327A610F93 Q33645841-D01AF71F-D3C4-4951-89FB-C47879F4E27D Q34631795-4F3A2C4A-F0F3-4760-B7F6-D0DE1F5FDF64 Q35000468-18E576AF-3079-44BD-8D82-8B0277A8C6DF Q35582104-8D575DFE-ADFE-4BCB-8B83-6047C1D5C2AD Q35640393-9BAEC9A0-C39E-4916-9AF7-EAA9BBAAB2C8 Q35736289-D375FF03-51EB-471A-971C-07E47B65E054 Q35748692-A4764F4A-8D47-442F-A1B0-28682D1866C8 Q35880923-55D71E16-94DE-4288-B6B6-154EDBC84BBB Q36407480-2112C3C4-75E8-421C-8D3C-E1D2473FB2E7 Q36429723-F41A3591-77FA-4F9A-B14A-4285478F9A37 Q36469671-BB85E29E-7E64-4F1B-AD88-CA19D2B1070A Q36639053-4F7B1983-B6A6-48CE-AF4B-82935287019C Q36684500-8098010D-7B1F-40AE-9DF5-C8DDE9208ACA Q36707846-B142CA49-5D90-4BF4-91BB-93FEA55EEA98 Q36793290-5F6B3281-183D-46F9-AE2E-47E89CB8CE1E Q36911493-71250977-F552-4EB9-9A05-465A9AF4AB40 Q36950052-438412C3-3371-4606-8C42-EC94DC1E1D14 Q36964464-0A54BD02-824A-4DF5-B9BE-CA6E9D0C5CE8 Q37125119-00C89654-F16D-4157-9EE6-6FBB603C2EBE Q37136999-C4E3B139-416D-45A3-8641-92D2534A0992 Q37238152-11424059-3EB7-41CA-93B6-C19643C734E8 Q37295150-A5E01721-9568-493D-8BCE-9586276228A8 Q37336365-1CBC2949-5AE4-4AF4-A68A-D40451A5FD5F Q37533977-2377F7C8-7F9B-4389-883E-1F14663D8C87 Q37586857-7B6D30C8-6346-4CC8-8EDF-F139C4D68BA3 Q37618909-F1256195-BF2D-4AA9-9E05-91631BE03226 Q37675882-0AD9B86B-1348-49D8-AE6B-BC6A167B5E7B Q37697843-70070EA0-A8D6-4074-B272-BD61FBBA5322 Q37752447-8454AB69-7438-4AAD-AF36-D74E013D77DE Q37785097-CC57D2F6-DF81-4D18-A054-66C03FEE89FC Q37810079-FDF6E533-33A3-4949-B08A-89A1E435E392 Q37942817-EFC5C7DE-6B1D-46B2-B6A4-67DC16A0E6D3 Q38260183-7AAB9229-082D-4F9F-9CA3-7425F6E6671E

P2860

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

Item

http://www.wikidata.org/entity/Q35848351

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

A phase 1/2 trial of high-dose ...... relapsed non-Hodgkin lymphoma

@ast

A phase 1/2 trial of high-dose ...... relapsed non-Hodgkin lymphoma

@en

type

Item

label

A phase 1/2 trial of high-dose ...... relapsed non-Hodgkin lymphoma

@ast

A phase 1/2 trial of high-dose ...... relapsed non-Hodgkin lymphoma

@en

prefLabel

A phase 1/2 trial of high-dose ...... relapsed non-Hodgkin lymphoma

@ast

A phase 1/2 trial of high-dose ...... relapsed non-Hodgkin lymphoma

@en

P1476

A phase 1/2 trial of high-dose ...... relapsed non-Hodgkin lymphoma

@en

P2093

Amrita Krishnan

http://www.w3.org/2001/XMLSchema#string

Andrew Raubitschek

http://www.w3.org/2001/XMLSchema#string

Andy Dagis

http://www.w3.org/2001/XMLSchema#string

Anne-Line Anderson

http://www.w3.org/2001/XMLSchema#string

Anthony Stein

http://www.w3.org/2001/XMLSchema#string

Arturo Molina

http://www.w3.org/2001/XMLSchema#string

Auayporn Nademanee

http://www.w3.org/2001/XMLSchema#string

Cheuk Kwok

http://www.w3.org/2001/XMLSchema#string

Christine White

http://www.w3.org/2001/XMLSchema#string

Dave Yamauchi

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma.

Radiolabeled antibody therapy of B-cell lymphomas.

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.

Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.

High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study.

Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas.

High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma.

High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission.

High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma.

P304

2896-2902

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2005-03-1310

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P50

Andrew Raubitschek

P577

2005-07-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7742754

http://www.w3.org/2001/XMLSchema#string

P698

16002426

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

phase II clinical trial

P932

1895300

http://www.w3.org/2001/XMLSchema#string

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

about

P2860

P2860

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P921

P932